{
  "company": "CIPLA",
  "report_date": "October 29, 2024",
  "filename": "CIPLA_transcript_Nov_2024.pdf",
  "quarter": "Q2",
  "fiscal_year": "2025",
  "management_team": [
    "MR. UMANG VOHRA - MD & GLOBAL CEO, CIPLA",
    "MR. ASHISH ADUKIA - CFO, CIPLA LIMITED",
    "MS. DIKSHA MAHESHWARI - INVESTOR RELATIONS,",
    "UMANG VOHRA - MD & GLOBAL CEO, CIPLA",
    "ASHISH ADUKIA - CFO, CIPLA LIMITED",
    "DIKSHA MAHESHWARI - INVESTOR RELATIONS,"
  ],
  "moderator": "Ladies and gentlemen, good day, and welcome to the Cipla Limited Q2 FY25 Earnings \nConference Call",
  "analysts": [],
  "qa_segments": [],
  "key_financial_metrics": {
    "revenue_inr_crores": "7051",
    "revenue_usd_million": "237",
    "growth_percentage": "9",
    "ebitda_margin_percentage": "9"
  },
  "business_highlights": [
    "partnership with large multinational corporations that sell categories of GLP-1 drugs."
  ],
  "extraction_metadata": {
    "extraction_date": "2025-08-03T01:08:55.409758",
    "source_file": "data\\cipla\\CIPLA_transcript_Nov_2024.pdf",
    "text_length": 46369,
    "extraction_method": "PyMuPDF + Regex parsing + Filename analysis"
  }
}